Profile data is unavailable for this security.
About the company
Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.
- Revenue in AUD (TTM)417.71k
- Net income in AUD-9.74m
- Incorporated2003
- Employees0.00
- LocationCynata Therapeutics LtdLevel 3, 100 Cubitt Street,, CremorneMELBOURNE 3121AustraliaAUS
- Phone+61 37067-6940
- Fax+61 39822-7735
- Websitehttps://www.cynata.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotron Ltd | 1.65m | -3.44m | 18.95m | 4.00 | -- | -- | -- | 11.52 | -0.0038 | -0.0038 | 0.0018 | -0.0003 | 0.7108 | -- | -- | -- | -148.49 | -77.12 | -234.15 | -92.61 | -120.34 | -127.14 | -208.89 | -238.85 | -- | -- | -- | -- | 14.94 | 8.93 | 1.61 | -- | -- | -- |
| Invion Ltd | 3.74m | -5.63m | 20.30m | 8.00 | -- | 1.37 | -- | 5.42 | -0.0009 | -0.0009 | 0.0006 | 0.0022 | 0.217 | -- | 2.65 | -- | -32.63 | -19.46 | -34.28 | -20.50 | -- | -- | -150.33 | -70.20 | -- | -- | 0.00 | -- | -9.54 | -0.7235 | -248.51 | -- | 171.96 | -- |
| Tryptamine Therapeutics Ltd | 1.21m | -4.32m | 21.78m | -- | -- | 3.24 | -- | 18.04 | -0.0162 | -0.0162 | 0.0039 | 0.0062 | 0.2368 | -- | -- | -- | -84.69 | -- | -120.26 | -- | -- | -- | -357.70 | -- | -- | -21.62 | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| LBT Innovations Limited | 1.31m | -3.74m | 23.13m | 17.00 | -- | 13.20 | -- | 17.66 | -0.0032 | -0.0032 | 0.001 | 0.0011 | 0.1712 | 0.0959 | 2.52 | -- | -48.89 | -34.86 | -78.03 | -38.53 | 88.63 | -- | -285.50 | -513.87 | 2.56 | -12.08 | 0.5686 | -- | -39.04 | -14.71 | 83.40 | -- | -69.50 | -- |
| Bioxyne Ltd | 9.33m | -12.80m | 26.61m | 16.00 | -- | 7.38 | -- | 2.85 | -0.007 | -0.007 | 0.0064 | 0.0018 | 0.7646 | 3.78 | 10.33 | -- | -106.39 | -56.02 | -134.91 | -72.46 | 36.44 | 40.00 | -139.14 | -85.52 | 1.18 | -40.41 | 0.0526 | -- | 80.70 | 34.32 | -559.75 | -- | 50.56 | -- |
| Amplia Therapeutics Ltd | 4.44m | -4.50m | 27.21m | 1.00 | -- | 1.73 | -- | 6.13 | -0.0226 | -0.0226 | 0.0222 | 0.0572 | 0.2647 | -- | 2.05 | -- | -26.86 | -25.13 | -32.90 | -27.42 | -- | -- | -101.48 | -206.74 | -- | -- | 0.122 | -- | 286.42 | 144.81 | 27.86 | -- | -6.91 | -- |
| Tissue Repair Ltd | 548.09k | -4.14m | 29.02m | -- | -- | 1.61 | -- | 52.95 | -0.0684 | -0.0684 | 0.0091 | 0.2983 | 0.0262 | 0.00 | 1.22 | -- | -19.81 | -24.20 | -20.72 | -25.29 | 100.00 | -- | -755.00 | -10,570.14 | 14.34 | -- | 0.00 | -- | 4,842.86 | -- | 0.8698 | -- | -- | -- |
| Noxopharm Ltd | 2.41m | -3.58m | 29.22m | 1.00k | -- | 5.32 | -- | 12.14 | -0.0086 | -0.0086 | 0.0082 | 0.0188 | 0.2847 | -- | 2.00 | -- | -42.31 | -43.24 | -48.67 | -52.58 | -- | -- | -148.64 | -170.07 | -- | -- | -- | -- | -60.33 | -9.37 | 76.24 | -- | -- | -- |
| Prescient Therapeutics Ltd | 687.57k | -8.24m | 32.21m | 3.00 | -- | 1.78 | -- | 46.85 | -0.0102 | -0.0102 | 0.0009 | 0.0224 | 0.0284 | -- | 3.31 | -- | -33.97 | -28.85 | -37.31 | -30.66 | -- | -- | -1,198.14 | -2,096.39 | -- | -288.97 | 0.018 | -- | 49.77 | 56.99 | -17.61 | -- | -- | -- |
| Cynata Therapeutics Ltd | 417.71k | -9.74m | 34.33m | 0.00 | -- | 4.73 | -- | 82.18 | -0.0543 | -0.0543 | 0.0023 | 0.0402 | 0.0305 | -- | 1.85 | -- | -71.18 | -39.49 | -81.37 | -42.96 | -- | -- | -2,332.89 | -515.32 | -- | -- | 0.00 | -- | 18.38 | 16.51 | 31.75 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| FIL Investment Management (Hong Kong) Ltd.as of 04 Aug 2023 | 9.51m | 5.27% |
